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Abstract
The significant challenges faced by modern-day medicine include designing 
a target-specific drug delivery system with a controlled release mechanism, hav-
ing the potential to avoid opsonization and reduce bio-toxicity. Nanoparticles are 
materials with nanoscale dimensions and maybe natural and synthetic in origin. 
Engineered nano-sized materials are playing an indispensable role in the field of 
nanomedicine and nanobiotechnology. Besides, engineered nano-sized particles 
impart therapeutic applications with enhanced specificity because of their unique 
bespoke properties. Moreover, such application-customized nanoparticles offer an 
enormous possibility for their compatibility with different biological molecules like 
proteins, genetic materials, cell membranes, and organelles at the nano-bio frame. 
Besides, surface functionalization with targeting moieties such as small molecule 
ligands, monoclonal antibodies, aptamers, cell-penetrating peptides, and proteins 
facilitate nanoparticle-based specific tissue targeting. This review summarizes 
some of the advances in nanoparticle-based therapeutics and theranostics. A better 
understanding of idealistic preparation methods, physicochemical attributes, 
surface functionalization, biocompatibility can empower the potential translation 
of nanomaterials from the ‘bench-to-bedside’. In modern-day medicine, engineered 
nanoparticles have a wide range of demands ranging from bio-imaging, theranos-
tics, tissue engineering, sensors, drug and nucleic acid delivery, and other pharma-
ceuticals applications. 2D and 3D mammalian cell-based assays are widely used to 
model diseases, screening of drugs, drug discovery, and toxicity analyses. Recent 
advances in cell culture technology and associated progress in nanotechnology have 
enabled researchers to study a wide variety of physiologically relevant questions. 
This chapter explores the properties of nanoparticles, different targeted delivery 
methods, biological analysis, and theranostics. Moreover, this chapter also empha-
sizes biosafety and bioethics associated with mammalian cell culture and discusses 
the significance of intellectual property rights from an industrial and academic 
perspective.
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Nanomaterials (NMs) are engineered chemical substances or materials with 
a particle size of 1–100 nm in diameter. Today NMs are extensively explored and 
engaged for commercial purposes in different fields, and many sophisticated NMs 
have shown great promise in biotechnology and biomedicine [1]. NMs display 
inimitable physicochemical attributes due to their size range in nanometers, high 
surface area, tunable surface charge, unique composition, various morphologies, 
and surface composition. Due to their remarkable physicochemical attributes, NMs 
are significantly different from their bulk materials of a similar symphony, allowing 
them to perform remarkably well with improved functionality, sensitivity, compe-
tence, and selectivity towards developing biomedicines. Various NMs are evaluated 
to get desired biomedical efficacy for nanomedicine-related applications, includ-
ing different metal nanoparticles, liposomes, quantum dots, polymeric micelles, 
dendrimers, and carbon-based nanoparticles. Two critical mechanisms for deliver-
ing drug-loaded NMs to the diseased sites are passive targeting and active targeting. 
A passive targeting mechanism happens via enhanced permeability and retention 
(EPR) [2]. Inactive targeting mechanism relies on surface functionalized NMs with 
various biomarkers that bind with receptors over-expressed at the pathological 
tissue [3].
The importance of cell culture advances in the medical sector has long been 
recognized. Mammalian cell culture (MCC) entails first isolating cells from a 
specific organ tissue and then creating a culture in a suitable artificial setting. 
Disaggregation using different methods may be used to obtain preliminary 
separation of cells from the identified organ tissues. The isolated primary cells 
are typically obtained from an in vivo setting, although some cells come as 
established cell lines. MCCs are widely used in the biomedical field to investigate 
numerous applications [4]. Since cell culture-based studies provide highly stable 
and repeatable results, researchers consider this technique as an essential model 
system in cellular and molecular biology. MCC needs an ideal environment 
for development, which can be divided into nutritional and physicochemical 
requirements.
Nutritional necessities comprise an adherent substrate or growing medium that 
offers conditions like essential amino acids, sugars, vitamins, minerals, growth 
factors, hormones, and gases (O2, CO2). All these features regulate physicochemical 
factors such as pH, osmotic pressure, and temperature. Many cell lines need solid 
or semi-solid support in the form of a substrate, while others can be grown in a 
suspension culture medium. These technologies have evolved as a means of assess-
ing the efficacy and side effects of novel active pharmaceutical ingredients (APIs), 
immunotherapeutic, and biopharmaceuticals [5]. Animal, plant, and bacterial cells 
are regularly cultured in fixed culture medium under precise laboratory circum-
stances; among this, animal-based cell cultures are more complex than others 
due to their genetic complexity. Directed differentiation of adult stem cells and 
pluripotent stem cell culture is another challenging aspect. Recent advances in stem 
cell culture technology have provided significant input for the successful culture of 
tissue-mimicking 3D organoids [4, 6].
In recent years, nanotechnology (NT) and associated disciplines have gained 
rapid escalation in biomedical implementations such as diagnosis, testing, track-
ing, drug delivery, nanomedicine, medical implants, and electronics due to their 
camaraderie with biological entities. Biomedicine embraces the design and syn-
thesis of NMs, along with other nanoparticles (NPs) and nano-devices [7]. Once 
properly formulated, NMs show their natural aptitude to traverse with the blood 
flow via various routes based on their attributes and eventually get access to all the 
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organs. Due to their intrinsic biocompatible interactions, the NPs exhibit unique 
physicochemical attributes associated with lesser immunogenicity and non-toxicity. 
There are numerous advantages of using NMs for various biological applications: 
i) it increases the concentration of drug in the pathological tissues and control 
the slow release of the drug; ii) it solves issues connected to the low solubility and 
bioavailability of the drug; and iii) enhanced biodegradability and biocompat-
ibility iv) drugs/genes/imaging agents can be easily loaded due to their tunable 
surface functionalities [1, 7, 8]. Imaging agents could endow in vivo drug track-
ing ability to determine drug delivery efficacy during treatment. In recent years, 
various nanoparticles such as liposomes, polymers, metal nanoparticles, inorganic 
nanoparticles have been developed for selectively targeting tumor cells and other 
pathological tissues without causing any destruction to healthy cells or organs. In 
this chapter, the application of nanotechnology and Intellectual property rights 
(IPR) prospects of mammalian cell culture will be discussed in the subsequent 
sections.
2. Compatibility of nanomaterials towards biological interactions
NMs attract considerable interest due to their unique, tunable, versatile physi-
cochemical properties, easy preparation methods, biocompatibility, and surface 
functionalization [1]. Nonetheless, the compatibility of the nanoparticles with 
biological entities constitutes the most fundamental phenomenon and highlights 
the importance of basic research [9]. Most bio-applications, including drug deliv-
ery, bioimaging, and treatment, start from the attachment of nanoparticles onto 
the target cells. The biocompatibility of nanoparticles depends on the physical and 
chemical attributes like diameter, shape, composition, concentration, functional-
ized moieties, and surface potential (Figure 1) [10]. Among the various NMs, 
Quantum dots have risen as an innovative bio-imaging tool due to their unique tun-
able physicochemical attributes. Existing research has guided the development of 
versatile quantum dots that are highly fluorescent and stable under diverse biologi-
cal circumstances. Moreover, quantum dots with enclosed amphipathic polymers 
have been developed and surface-functionalized with receptor targeting ligands 
for bio-imaging and drug-delivery in animal models. Fascinatingly, these materials 
were found to be compatible with the cells. However, their complete chronic in vivo 
genotoxicity, blood, and organ compatibility need to be assessed [1, 7, 11].
Polymeric nanoparticles have drawn considerable attention in drug and gene 
delivery, tissue engineering, and many biomedical applications due to their non-
toxic nature and high compatibility to biological systems. They are colloidal in 
nature and composed of natural or synthetic, or semi-synthetic polymers. In this 
perspective, biodegradable nanoparticles of the highly compatible triblock copoly-
mer are used for non-viral gene transfections [3].
Liposomes are another popular nanomaterial drug delivery system that is best 
documented and adapted owing to their bio-congenial physicochemical proper-
ties [12]. Liposomes consist of unilamellar/ multilamellar lipid bilayers having an 
aqueous core inside. The nanoscale carrier system offers substantial advantages 
such as biodegradability, biocompatibility, ease of synthesis, less toxicity, sus-
tained drug release, and the ability to incorporate hydrophilic and hydrophobic 
drugs. Liposomal-surface modification is a crucial strategy for targeted therapy 
and especially for cancer treatment [13]. Seventeen liposomal formulations are 
clinically approved for cancer, inflammation, infectious diseases, antibiotic drugs, 
and anesthetics, while several liposomal formulations are under various phases of 
clinical trials [12, 13].
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Despite several encouraging biomedical implementations of nanoparticles, the 
biocompatible assessments including, complete acute and chronic toxicological 
evaluation of NMs, are inadequately comprehended. Additionally, the toxicity of 
Figure 1. 
Precision of targeted drug delivery using nanocarriers and bio-compatibility. Nanoparticle based drug delivery 
platform depends on surface functionality, size and shape and surface charge and composition.
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the nanoparticle design aims to find out favorable physicochemical attributes of 
different materials. Hence, the active bio-molecule with biological entities must 
be highly allied to the nanoparticles approaching direct contact with biological 
objects rather than its transient initial distribution. Much to our intrigue, various 
nanoparticles - liposomes, lipoplexes, polymeric nanoparticles, polyplexes, metal 
nanoparticles, metal oxides, dendrimers, and quantum dots are wisely engineered 
for their medical application like diagnosis, drug and gene delivery, tissue engineer-
ing, and biosensing [8, 13, 14]. Moreover, it is unavoidable to thoroughly assess and 
investigate compatibility/unwanted toxicity with nanoparticles to bring clinical 
success. The subsequent section will relate to how the physicochemical properties 
of engineered nanoparticles can be persuaded towards accomplishing the desired 
biological aspiration lacking any toxicological impact.
2.1  Tunable physicochemical attributes of nanomaterials compatible with 
biomedical applications
Nanoparticles exhibit outstanding physicochemical attributes which can be 
manipulated to harness the best possible benefits out of them - their tunable 
diameter, high surface area, various morphologies, different concentrations and 
compositions, surface functionalization, etc. [15] (Figure 1). Interactions of NMs to 
the cell surface, their internalization, and subcellular localization, communication 
with the cells eventually contribute to therapeutic or adverse effects. Understanding 
the physicochemical attributes of NMs and their interactions with biological 
entities can help design superior NMs for further applications. We are jotting down 
the relevant physicochemical attributes of nanoparticles, which may modulate 
their function in therapeutic or toxicity aspects; thus, they need to be engineered 
wisely [16].
2.1.1 Nanomaterials size
For engineered nanoparticles, the primary crucial feature is their dimensions/
size, which partially governs other physicochemical characteristics. The reduced 
diameter of the nanoparticles, provide possibilities for high cellular localization 
making them interact with cellular tissues, especially pathological tissue to a 
greater extent to attain specific biological outcome for the remedial purpose. Size-
dependent bio-distribution studies were performed using three different sizes con-
taining (20, 50, and 200 nm) drug conjugated silica nanoparticles. It revealed that 
nanoparticles having 50 nm diameter had the highest tumor localization, enhanced 
cancer tissue retention, and slower clearance [16]. Moreover, nano-sized particles 
preside over their pharmacokinetics, are predictable to traverse biological barriers, 
which is not possible for bulk particles. Besides, ~50 nm diameter particles showed 
higher efficacy because of active engagement to the biological tissues, modulating 
pathways, and cellular activities [17].
2.1.2 Nanomaterials surface charge
The surface charge is a unique character of NMs to manage its therapeutic and 
toxicological effects and plays a significant role in electrostatic interactions of NMs 
and living entities (Figure 1) [10]. Besides, the cellular localization pathways and 
tissue interactions are regulated by the surface charge of the nanoparticles, thus 
playing a significant role in the compatibility and cellular toxicity. Several reports 
suggest that nanoparticles with a positive charge highly interact with the negatively 
charged cell membranes and provoke genotoxicity [18]. Positively charged cationic 
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liposomal drug and gene delivery systems have been extensively studied for the 
last decade. It was recently shown that cationic lipoplexes are not showing any 
genotoxicological aberrations in the Swiss albino mice. Typically, cell membranes 
are anionic in nature; thus, negatively charged NMs have very slow cellular inter-
nalization compared to neutral and positive nanoparticles [14]. Surface potentials 
of metal particles in regulating different tumorous and non-tumorous tissue types 
are also established. Several studies have suggested the role of the surface potential 
of different nanoparticles and their interactions with the biological entities and 
how surface charge modulates their biological functions, which shed light to design 
and engineer nanoparticles for a selective cellular target for various diseases with 
minimal toxicity [16, 18].
2.1.3 Surface functionalization
Nanoparticles play a vital role in promoting intracellular delivery of encap-
sulated therapeutic agents and increase their retention in pathological tissues 
compared to healthy tissues [1]. Surface functionalization with suitable receptor-
targeted ligands using different methods results in the formation of targeted 
nanoparticles with improved therapeutic response and minimized off-target side 
effects by prolonging their circulation time in blood, increasing target specificity, 
cellular uptake, and drug accumulation in the tumors (escaping lysosomal degrada-
tion and enhancing stimuli-responsive drug release) (Figure 1) [17, 19]. Depending 
on their application, nanoparticles are functionalized with different targeting 
ligands either by directly conjugating ligands to PEGylated nanoparticles through 
post-insertion technique or by covalent grafting on the surface of the nanoparticles. 
In this context, surface functionalization of nanoparticles with antibodies, pep-
tides, folic acid, aptamers has been extensively studied. This prompts scientists to 
design and engineer nanoparticles for selective targeting and high retention in the 
tumor tissue rendering minimal toxicity to the vital organs [19, 20].
3. Mechanism of targeted drug delivery using nano-carrier
Nanoparticles play a vital role in promoting intracellular delivery of enclosed 
therapeutic agents and increase their retention in the different pathological tissues 
compared to other therapies [21]. Like normal tissues, tumors need nourishments 
by means of food and oxygen and a capacity to remove metabolic excretes and 
carbon dioxide. Diverse patterns of tumor-associated neovascularization, obtained 
by angiogenesis, cope with these demands. Primary conservative treatment modali-
ties involved in cancer treatment are surgery, radiotherapy, and chemotherapy, 
while additional therapies such as immune therapy, targeted therapy, and hormone 
therapy are chosen depending on the type of tumor [22]. On the other hand, the 
failure of chemotherapeutic drugs to specifically target cancer tissue hinders many 
treatment modalities. It is habitually faster and economically cheaper to design an 
existing drug to encapsulate in a delivery system a more effective way to superior 
targeting of tissues than to invent a completely new one. The drug delivery mecha-
nism can be classified into passive and active, respectively.
3.1 Nanoparticle drug delivery by passive targeting
Passive targeted drug delivery mainly depends on the physicochemical attributes 
of the NMs, such as shape, diameter, surface potentials, and pathophysiologi-
cal conditions of the disease microenvironment. Intravenously injected drug 
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encapsulated NMs tend to disperse throughout the body evenly [23]. However, 
unlike normal tissues, tumor cells tend to take up particles of a definite diameter to 
a greater extent than healthy cells due to the arrangement of capillary endothelial 
cells, accumulating extravasated molecules in the interstitial spaces poor lymphatic 
drainage increases the permeation and accumulation of drug-mediated NMs. This 
type of NMs accumulation in the tumor region is known as the EPR effect [1, 2]. 
The EPR effect is influenced by physicochemical attributes of NM including par-
ticle diameter, shape, and surface potentials greatly influence the circulation time, 
penetration speed, tumor localization, and intracellular internalization.
Particle diameter plays a critical role in achieving effective drug delivery as 
it enhances permeation and circulation time and reduces renal clearance. For 
example, phagocyte cells facilitate larger particle uptake, while non-phagocytic 
cells favor the uptake of smaller particles. PEGylated NPs reduced plasma protein 
adsorption on their surface and reduced hepatic filtration when their size is smaller 
than 100 nm [24]. Particle diameter with 20–200 nm effectively enhances the 
permeation in both hyper-permeable and poorly permeable tumors, and particles 
with less than 6 nm avoid renal clearance. The NPs surface potentials could play a 
vital role in circulation and cellular localization [24, 25]. NPs with positive surface 
potentials such as cationic liposomes induce non-specific interactions with blood 
components and aggregation of liposomes results in a reduction of EPR effect and 
increased renal clearance. However, positively charged NPs are more readily taken 
up by cancer cells. Whereas anionic and neutral surface potential-bearing NPs 
circulate longer in the blood circulation [1, 2, 24].
Besides, Polyethylene glycol (PEG) polymer is used as a stabilizer (stealth lipo-
somes) that increases the circulation time in blood up to 24–48 hours and improves 
in vivo stability [26]. PEG-coated liposomes induce the ‘steric stabilization effect’ 
by creating hydrophilicity on the surface of liposomes that shield surface charge 
and increases the repulsive forces between liposomes and blood components. Thus, 
it prevents aggregation of liposomes and opsonization by the reticuloendothelial 
system, macrophages, mononuclear phagocytic cells and prolongs their systemic 
circulation. On the other hand, PEG-coated liposomes induce PEG-specific IgM 
antibodies, enhancing hepatic uptake and rapid clearance of liposomes from 
systemic circulation on subsequent administration. PEG corona produces steric 
hindrance with tumor cells that prevent effective internalization, which could be 
minimized by using short PEG chains with molecular weight less than 1000 Da or 
by designing PEG with enzyme-cleavable bound or tumor-targeting ligands  
[20, 26]. To investigate the influence of shape on the cellular localization of NPs, Li 
et al. conducted large-scale molecular simulations to evaluate different NP geom-
etries with identical surface area, ligand-receptor interaction strength, and PEG 
grafting density. They observed that spheres exhibited the fastest internalization 
rate, followed by cubes, while rods and disks were the slowest. Many liposomal 
formulations have received clinical approval, like Doxil, Abraxane, etc. However, 
nanoparticles grafted with PEG prolong the systemic circulation of the particles 
and induces the EPR effect in tumor cells, but lack of target specificity often results 
in reduced therapeutic efficacy [27]. Because of that, more than 95% of passively 
targeted formulations fail to go bench to bedside.
3.2 Nanoparticle-based drug delivery by active targeting
An ideal nanoparticle delivery system should be proficient at reaching, recog-
nizing, and delivering its payload to determined morbid tissues and avoid drug-
induced toxicity to healthy tissues [7]. Therefore, functionalizing specific targeting 
moieties on the surface of nanoparticles is the most usual plan. Nanoparticles are 
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functionalized on their outer surface by targeting moieties such as small molecule 
ligands, monoclonal antibodies, aptamers, cell-penetrating peptides, and proteins 
that are internalized into morbid cells by interacting with cell surface receptors like 
folate receptors, transferrin receptors, tyrosine kinases like EGFR, and so on [28] 
(Figure 1). Cell surface receptors that are significantly overexpressed in diseased 
cells, compared to normal healthy cells, provide a potential target for the design and 
development of actively targeted drug delivery and help to reduce off-target effects 
[7, 17]. These ligand moieties can interact with target-specific diseased cells and 
protect nanoparticles from enzymatic demolition.
Targeted drug delivery significantly minimizes the toxicity and induces patient 
compliance with less frequent dosing. Active targeting depends on ligands bound to 
the NP surface to improve their uptake selectivity and protect NPS from enzymatic 
destruction. The main principle of active targeting involves functionalizing an 
NP with a ligand that binds to a molecule overexpressed on cells. Ligands with a 
high binding affinity to a specific cell type exhibit higher delivery efficiency. One 
important thing to consider is that healthy cells still express the same molecule, and 
as healthy cells greatly outnumber, the chances of NPs missing their target will also 
increase. An intelligent selection and functionalization with multiple ligands can 
effectively mitigate the problem. Apart from this, active targeting mainly deter-
mined the kind of nanoparticle carrier, ligand targeting specific receptors, func-
tional agents used for linking a ligand to the nanoparticles, hydrophilic polymers, 
and encapsulated active ingredients [28, 29].
Targeting tumor cell surface receptors is a common approach in active targeting. 
Nanoparticles were linked with targeted ligands for targeting specific cell recep-
tors and thus upregulated the intracellular localization and therapeutic efficiency. 
Liposomes are conjugated with antibodies, a Y-shaped glycoprotein, or its frag-
ments often termed as immunoliposomes, increasing the specificity of liposomes by 
targeting antigen-presenting cancer cells, which undergo endocytosis and destroy 
cancer cells followed by immune system clearance [28]. Folate receptors are mem-
brane proteins overexpressed by various tumor cells. Folic acid is a ligand for target-
ing folate receptors, which pose high affinity, stability, and conjugation capacity 
[30]. It is conjugated with nanoparticles and a PEG spacer that inhibits steric 
hindrance between the cells and liposomes, which helps to increase cellular uptake 
and drug delivery of folate-targeted anticancer drugs. Targeting folate receptors 
with folic acid ligands helps deliver therapeutic and imaging agents effectively to 
the requisite site. Endothelial growth factor receptors (EGFR) overexpressed in 
solid tumors like non-small cell lung cancer, colorectal, squamous cell carcinoma 
of the ovary, kidney, head, neck, pancreas, prostate, and breast cancers can help 
in designing EGFR targeted drug delivery system. Antibody fragments used for 
targeting EGFR are functionalized on nanoparticle surfaces in order to acquire high 
targeting specificity [31]. Fibroblast growth factor receptors are overexpressed in 
cancers like lung, prostate, bladder, etc. Several groups have reported remarkable 
interaction of FGFs conjugated liposome with FGFR and discussed in detail  
[32, 33]. Overexpression of CD44 is observed in cancers like leukemia, ovarian, 
colon, gastric, pancreatic, and epithelial cancers. Hyaluronic acid acts as a ligand 
for CD44 and is used to deliver gemcitabine and DOX encapsulated within the 
liposomes [34].
Targeting the tumor microenvironment is another approach in active target-
ing, and one aspect is targeting the tumor vasculature instead of the tumor. 
This approach helps in the targeted destruction of neo-angiogenic blood vessels 
essential for tumor growth and metastasis [29, 35]. Vascular endothelial growth 
factor receptors (VEGFR) play a significant role in tumor angiogenesis and vas-
cular permeability and regulate other aspects of tumorigenesis. Bevacizumab, a 
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monoclonal antibody approved by USFDA, is used as an anti-human VEGF for 
targeting VEGFRs and FGFRs tyrosine receptors for active targeting [29]. Vascular 
cell adhesion molecules (VCAM-1) are cell adhesion molecules (CAMs) present 
on the endothelial cells responsible for inflammation. VCAM-1 is overexpressed 
in cancers like non-small cell lung cancer and tumor vasculature. Anti-VCAM and 
Fab-conjugated liposomes have high cellular uptake into Human Umbilical Vein and 
Endothelial Cells (HUVEC) compared to conventional liposomes [36].
Matrix metalloproteases (MMPs) are calcium-dependent endopeptidases 
involved in remodeling extracellular matrix, tumor invasiveness, and metastasis by 
modulating the formation of new blood vessels [37]. Conjugating MMP-2 cleavable 
peptides to liposomes loaded with cell-penetrating peptides increase the tumor 
selectivity. αβ-integrins are the heterodimeric transmembrane glycoproteins that 
facilitate the adhesion of endothelial cells with adjacent tissue and blood vessels. A 
tripeptide Arg-Gly-Asp (RGD) exhibited high specificity for αvβ3 integrin helps in 
developing integrin targeted liposomes, which inhibits adhesion and angiogenesis 
in the tumor microenvironment (TME) [38]. Active targeting amends the intuitive 
patterns of a nanocarrier, directing to the specificity of the pathological tissue. 
In contrast, passive targeting delivery depends on the natural distribution of the 
therapeutic motifs and the EPR effect. Both the targeting mechanisms depend on 
blood circulation and the location of initial drug delivery. However, rare commer-
cial advances are made using actively targeted NPs [39].
4. Nanomaterial and their application from biological analysis
4.1 Nanomaterial-driven faster and more accurate cell analysis
Early detection and diagnosis can play a pivotal role in the battle against many 
diseases. Scientists harness the unique attributes of nanomaterials to generate 
novel molecular contrast agents for in vivo imaging, sensing, measuring response 
to therapy, and liquid biopsy to study disease initiation, progression, and thera-
peutic response. Nanotechnology has a spacious range of accurate cell analyses. As 
described above, nanotechnology facilitates the development of desired formula-
tions for individual cell analysis and their specific treatment applications, develop-
ing only one of its kind of applications for cell sensing/sensors, imaging, delivery, 
and diagnosis [39]. Since the importance of accurate cell analysis for nanoparticles 
is the latest approach, there is a big void for more discoveries and optimizations in 
various bio-applications.
4.2 Nanomaterial and in vivo imaging
The main lacunae in cancer treatment are a late diagnosis. The resolution of cur-
rent imaging methods is low and can detect cancers at the late/ advanced stage or 
metastasized. A tissue biopsy can only help physicians to ascertain the tumor type 
and characteristics. Detection becomes even more challenging when metastatic 
modules and micrometastasis need to be identified. In vivo imaging enables us to 
non or minimally-invasively delve deep into the patient’s tissue and is becoming 
increasingly popular for basic research and clinical applications. In vivo, molecular 
imaging focuses on obtaining spatiotemporal information about molecules of 
medical interest or biomarkers within a living body in real-time. Molecular in vivo 
imaging relies on contrast agents or medium that increases the contrast of physio-
logical structure and enhances the sensitivity of detection. Different contrast agents 
are used for different in vivo imaging techniques including, radiocontrast, magnetic 
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resonance imaging (MRI) contrast, ultrasound contrast, and optical contrast agents 
[40]. Precision diagnostics is dependent on high-resolution and high-contrast 
images. Nanomaterials are critical players in the generation of advanced contrast 
agents or media. Imageable nanoparticles can be classified based on their applica-
tions in nuclear, magnetic, optical, and acoustic imaging modalities. Moreover, 
NP-based contrast agents may be designed to integrate multiple detection modules 
and target specific cells. The advantages of nanoparticle-based contrast agents 
include enhanced specificity, increased photo and chemical stability, longer circula-
tion time, engineered clearance pathways, and multimodal applications. The main 
in vivo imaging modalities include MRI, computed tomography (CT), positron 
emission tomography (PET), single-photon emission computed tomography 
(SPECT), ultrasonography (US), near-infrared fluorescence (NIRF), and two-
photon intravital microscopy [41–43].
4.3 Nanoparticles as bio-sensors
By virtue of their unique properties, NPs make them ideal for their use for nano 
bio-sensing applications with enhanced sensitivity. Nanoparticles are widely used for 
detecting cells and pathogens, separating pathogens, recognize different biological 
substances, and detecting molecular and cellular functions [41, 42]. Accurate and 
professional separation of desired cells from the composite of various cell mixtures is 
essential for numerous biological applications. Nanoparticles have been investigated as 
a promising and very sensitive tool for the specific identification of cells. Identification 
and incarceration of metastatic cancer cells in the circulation can help understand 
and a strong analytical biomarker for various metastatic cancers, which can change 
the patient’s prognosis. Nanoparticle-based methods are more frequently used for 
the identification and capture of metastatic circulating cancer cells. In this technique, 
magnetic nanoparticles were used to specifically track and separate the cells by using 
a ligand-receptor-based mechanism [42]. These techniques can also be used for the 
white blood cells with an anti-CD45-APC as a nanoparticle targeting ligand [44].
Additionally, various nanoparticle-based technologies have been investigated 
as a sensor for the identification and selection of various pathogens. The most 
frequently used method for finding bacteria is magnetic biosensors that involve 
immunological mechanisms using magnetic nanoparticles functionalized with 
antibodies against surface antigens. Many researchers have been utilizing small 
molecule tethered nanoparticles to analyze the bacteria successfully. Magnetic 
glyco-nanoparticles mediated particles could detect bacteria within 5 minutes, 
including subtraction from the sample by the bacterial interaction with carbohy-
drates on mammalian cell surfaces [41].
4.4 Nanoparticles as imaging agents
Nanoparticles have been investigated as imaging agents due to their exceptional 
physicochemical attributes for various biomedical applications such as cancers and 
cardiovascular diseases. Fluorescent labels can be easily conjugated to the surfaces 
of the nanoparticles by various chemical methods to design a wide range of imaging 
agents for dynamic in vitro and in vivo cellular imaging [45, 46]. Due to their passive 
and active targeting nature, nanoparticles can easily identify their specific biomark-
ers and accumulate at high concentrations in the targeted tissue. The high capability 
for nanoparticle modification and retention properties in the specific tissue region 
empowers their utilization as imaging amplifiers. Quantum dots are the most 
promising fluorescent labels for cellular imaging among all nanoparticles due to their 
inherent near infra region light emitting nature, reducing autofluorescence [47].
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RGD peptide conjugated self-emitting quantum dots can be used for specific 
integrins highly expressed in tumors. The targeted nanoparticle has been examined 
for complex imaging competence, like imaging various molecular targets using 
different spectral emissions specific nanoparticles. Recently, nanotechnology 
has been used for imaging metastatic tumor cells in circulation, tumor cells, and 
their vasculature, stem cells, and lymph nodes [48]. Che et al. designed shortwave 
infrared window (SWIR)-responsive QDs for bone-specific real-time in vivo and ex 
vivo imaging and could visualize the significant bone structures Balb/C nude and 
Balb/C mouse [49]. The use of specific nanoparticles can help accurately decipher 
and image the gram-negative and gram-positive bacteria. Due to their fluorescence 
characteristics and specific bacterial cell wall interactions, they can be used in a 
wash-free fashion in bacterial imaging, which is significant for health care, food 
processing, and medical hygiene.
4.5 Application of nanoparticles in theranostics
Theranostic NMs are designed by the consolidation of diagnostic and thera-
peutic abilities in one biodegradable nanoparticle [50]. Novel theranostic materials 
should have the following properties; i) highly compatible with biological entities, 
ii) proficiently and precisely accumulate in desired morbid tissue, iii) describe the 
biochemical and morphological attributes of maladies, iv) exhibit minimal toxico-
logical effects, v) and deliver a sufficient amount of therapeutic agent. Several tech-
niques have been used to functionalize the surface of nanoparticles for theranostics 
use. Surface functionalization may include imaging agents, drugs, therapeutic 
cargo, nucleic acid, and contrast agents by either chemical functionalization or 
by biofunctionalization. Chemical functionalization depends on chemical cross-
linking, while biofunctionalization of nanoparticles relies on bioinspired ligands 
obtained from natural phytochemicals). The use of nanotechnology offers a prom-
ising alternative for the diagnosis of various cancers. Various investigations convey 
that nanoparticles could be engineered for advanced diagnostic agents to detect 
cancers [51]. Double drug encapsulated liposomes can be functionalized to enhance 
theranostic efficacy [51, 52]. Multifunctional Metal nanoparticles can serve as a 
unique platform for cancer theranostics. The range of use of metal nanoparticles 
includes MRI imaging, biological catalysis, magnetic hyperthermia, magnetic drug 
delivery, photo-responsive drug delivery, and cell separation. Metal nanoparticles, 
including, Polymer-NP constructs containing Gd3+ complexes, Fe3 + − terpyridine 
complexes, and polymeric shell-based contrast agents, are widely studied for their 
theranostic use as MRI contrast. Magnetic particle imaging (MPI), a novel imaging 
technique, is based on the analysis of iron oxide NPs in response to a magnetic field.
Cheng et al. used GE11, a novel peptide with EGFR binding affinity and com-
plexed with doxorubicin-loaded liposomes, and observed higher liposomal uptake 
and accumulation than, unconjugated liposomes using NIRF [53]. In another 
study Song et al. designed a multifunctional targeting liposome for targeting lung 
cancer. Octreotide (OCT), a synthetic 8-peptide analog of somatostatin, was used 
to surface coat the liposome for enhanced binding with the somatostatin recep-
tors overexpressed in a subset of tumors. Double anti-cancer drug (Honokiol and 
epirubicin) co-encapsulated liposomes showed enhanced OCT- somatostatin 
receptor binding and in vivo response [54]. Cittadino et al. designed a theranostic 
long-circulating liposome with co-loaded prednisolone phosphate and an amphi-
philic paramagnetic gadolinium contrast agent [Gd-DOTAMA(C18)(2)] for MRI 
monitoring of melanoma. The theranostically engineered liposomes showed 
long-term MRI-based detection without a loss in drug action [51]. The theranostic 
nanoparticle could assist in the patient’s pre-selection, a prediction for responding 
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to nanomedicine therapy. Moreover, nanomedicine-treated patients could be moni-
tored throughout treatment duration while using nanomedicine formulations [39].
5. Biosafety and bioethics issues in handling mammalian cells
Biosafety is a notion that requires protecting human health and the surroundings 
of pathogenic and genetically modified mammalian cells or organisms used in the 
research. Mammalian cell culture is identified as a shelter for infectious etiologic 
substances, and it should change the compliance with containment measures 
recommended for the etiologic agent itself. The utility of cell cultures comes under 
the preview of a range of regulatory provisions that consider the estimation of 
biological risks. Genetically modified mammalian cell cultures were used in differ-
ent continents; in that case, a bio-safety assessment should be regulated. The major 
guidelines issued to mitigate the biological risks for the users and environment are 
mainly by the World Health Organization; the Centers for Disease Control and 
Prevention, and the Swiss Expert Committee for Biosafety. Several countries or 
geographical zones have different directives; for example, in Europe, genetically 
modified research was brought into the regulatory provision (Directive 2009/41/
EC). Mammalian cell culturing activities focusing on developing pharmaceutical 
drugs are covered by the Regulation (EC) No 726/2004 and its amendment laying 
down actions for the authorization and direction of medicinal goods for human 
and animal use. 3D cultures, especially organoid culture systems, are regularly 
used for disease modeling and studying nanomaterial-based physiological effects. 
Human Pluripotent stem cell-derived organoids are being generated from various 
human cell types and need better bio-safety and bioethics assessment. It must be 
ascertained that rules focusing on extenuating the biological risks for laboratory 
researchers, public health, and the environment falls under the preview one or sev-
eral regulatory provisions based on biological risk assessment. Here, we are going to 
address the bio-safety issues involving mammalian cell cultures.
5.1 Bio-safety assessments of mammalian cell cultures
Biosafety refers to the way of protecting scientists, the health of other humans, 
and the environment from the probable side effects of microorganism, pathogenic, 
and genetically modified organisms and cells from human and mouse backgrounds. 
Laboratory biosafety uses safety principles and techniques to minimize the health 
hazard from accidental exposure or unplanned spillage while using infectious 
agents, toxins and other biological hazards in the laboratory setting. The bio-safety 
assessments applied to mammalian cells depend on a systematic assessment of the 
intrinsic attributes of the mammalian cultures like genetically modified cells and 
contaminated or intentionally infected with pathogens. Figure 2 shows a sum-
mary of the biosafety assessment and management process that is followed while 
handling cell culture-based experiments. This also considers an exposure analysis, 
which means that type of exploitation carried out with the cultures should be con-
sidered. The risk analysis of cell cultures that carry the pathogens follows the same 
methods for analyzing pathogens themselves. Primarily, the inclusive depiction of 
major pathogens is measured by the subsequent guidelines (i) pathogenicity and the 
infectious dose (ii) mode of transmission, (iii) host range, (iv) the epidemiology, 
potential reservoir and vectors, and the ability to zoonosis (v) the stability and the 
resilience of the pathogens in the surroundings.
Moreover, information related to the physicochemical properties of the patho-
genic organism is considered, such as (i) susceptibility to disinfectants, (ii) physical 
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inactivation, and (iii) drug susceptibility (e.g., sensitivity and known resistance to 
antibiotics or antiviral compounds). Lastly, aspects related to the disease caused 
by the pathogen are also to be taken into consideration. This includes (i) the avail-
ability of effective prophylaxis, (ii) the availability of efficient therapy, and (iii) 
any reported case of laboratory-acquired infections (LAIs). Even though underem-
phasized, several LAIs of mammalian cell cultures (or having virus suspension) has 
appeared. Among all, the exposure to vaccinia viruses amplified in mammalian cell 
cultures causes infections to laboratory researchers. Guidelines have been developed 
recently to work cautiously with vaccinia viruses and take a count of LAIs relating 
to this virus [55].
Understanding and having a complete analysis of the intrinsic infections of cell 
cultures help to perform well and safe mammalian cell culture. To assess biologi-
cal risks connected with the mammalian cell cultures, three intrinsic properties 
related to cell cultures should be considered: the species of origin, the cell type or 
type of tissue (the organ of origin of the cell line), and the status of the culture. 
Correspondingly, mammalian cells other than human cells render less risk;  
still, some infectious agents are proficient at crossing one species to another species, 
leading to zoonosis. Highly reported infections of viruses comprise hantavirus, 
hemorrhagic fever viruses, bird Influenza virus, and severe acute respiratory 
syndrome (SARS) associated virus. Primary cell cultures are created from organ 
tissues. Highly characterized mammalian cells give the lowest risks compared 
to primary cultures or less characterized cell lines. Mammalian cells originat-
ing from different laboratories without having any proof of identity may cause 
cross-contamination and pathogen spreading problems, and thereby proper risk 
assessment and cell characterization are warranted [55, 56]. Several techniques are 
available for the bio-safety assessment, like RT-PCR, flow cytometry, cytogenetic 
analysis, DNA fingerprinting, and iso-enzyme analysis. Adventitious contagions 
of mammalian cell cultures are a vital problem for any activity that involves cell 
culturing. Contamination agents for cell cultures are bacteria, fungi, mycoplasms, 
parasites, viruses, prions, and even other animal cells. Modulated experimental 
Figure 2. 
Flow diagram illustrating the summarizing the biosafety assessment and management process while handling 
cell culture-based experiments. Flow chart is inspired by reference [55].
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results suggest that they spoil the cell cultures. Bio-safety point of view modified 
mammalian cell cultures for laboratory research, production purposes, or diagnosis 
purposes they may give support for contaminating materials that cause harm to 
human health.
5.2 Bioethics and mammalian cell culture
The futuristic technologies in bio-medicine are changing the current concepts 
and opening up new dimensions. Interestingly as new optimistic channels are open-
ing and expanding, the issues of bioethics are becoming accurate and pertinent. 
Bioethics is the use of ethical principles in the field of medicine and healthcare. 
The rational application of ethics in evaluating mammalian cell culture-based 
experiments is highly warranted, especially during the emerging waves of change in 
biomedicine. Increased International cross-connection to facilitate open discussion 
in bioethics and related fields across cross-cultural aspects in bioethics is vital [57]. 
Several relevant questions arise regarding the private and sensitive use of source 
data for cells, moral concerns regarding the uses of embryonic and fetal tissue, 
genetic manipulation, gene therapy, mixing of animal and human cells, tissue 
banking, legal and intellectual properties associated with ex vivo tissue-engineered 
cell-based products, an extension of human-ness, etc.
Regarding the humane use of animals, the National Institutes of Health has 
issued policies as mentioned in the Public Health Service Policy on Humane Care 
and Use of Laboratory Animals. FDA Human Tissue Task Force and the Center for 
Biologics Evaluation and Research (CBER) regulates the use of human cells or tissue 
for implantation, transplantation, infusion, or transfer into a human recipient. The 
International Society for Stem Cell Research (ISSCR) has also released guidelines 
for stem cell research and clinical translation. The United States Congress and state 
legislatures are instrumental in creating laws concerning bioethics. Several profes-
sional bioethics organizations, including the American Society for Bioethics and 
Humanities, American Society for Law, Medicine, and Ethics, Canadian Bioethics 
Society, provide a platform for discussion over bioethics [57]. Several public institu-
tions supported by academicians and researcher-based initiative for propagating 
public dialog plays a vital role in educating the masses.
6. Significance of IPR on industrial and academic scale
Intellectual property rights (IPR) prevail in any primitive design of the human 
brain, such as methodical design. IPR mentions the lawful rights agreed to the 
designer for guarding his innovation for a definite period. These lawful rights grant 
special rights to the originator or his lender to exploit his idea for a specific period. 
It is well established that IPR participates in the financial system. It is furthermore 
overwhelmingly recognized that the intellectualism linked with the originality must 
be agreed due to value so that products come out of intelligence. The importance 
of the producer of the technology has turn into lofty and consequently guard the 
information against unauthorized persons, the use has become a measure, at least 
sometimes, that would make sure revitalization of the research, investments in 
developing the technology. IPR helps to look after funds, time, capital, endeavor 
invested by the producer of an intellectual idea; as a result, IPR, in this way, encour-
ages the profitable encouragement of a realm by encouraging positive competition 
and heartening trade and industry [58].
The industries have reputations in discussions about IPR strategies, and they are 
in the face line for controversies about the association among IPRs, R&D incentives, 
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cost, and right to use to supplies [59]. Although, some discussions on the critical 
issue are relatively little practical proof to support developing IPR policy. This 
experimental evidence on IP and products inspect practical issues are the primary 
sources of the data. The industrial sector is composite and much synchronized in 
the majority of economies. Looking cross-nationally, the contrast among the coun-
tries in their perspective on these essential policy affairs generates some additional 
provocations. In a cosmopolitan industry having control over research and devel-
opment conveniences in many countries, anticipating a successful transnational 
technology, goods are raised and developed internationally and are commercialized 
worldwide. Still, retails are nationalized, with no considerable uniformity across the 
nations in IPR authorities and various public health care organizations. IPRs may 
shore up significant discrepancies to price across the nations in returns and demand 
to prices. These discrepancies in the prices may potentially develop new local and 
global disagreements. Prominently, for any nation, the essential exchange in IPR 
regulation options is incredibly dependent on the organizations and function of its 
health care system.
While having a commendable collaboration, the complete fulfillment of a 
patent portfolio is to give equal rights for industry and academic institutions. 
In many countries, research organizations pursuing research in academic 
institutions, despite their most important work in society as a generator of the 
intellectual idea, the main concern is to be to deal with IP in a proficient mode. 
All academic institutions must become accustomed to this development to suc-
cessfully fulfill the responsibility entrusted to a national or regional innovation 
ecosystem.
On the supply side, goods safety, supervision of manufacturing, and legal 
frameworks leading technology transfer among public-funded academic institu-
tions and money-making industries playing an equal role in determining competi-
tion. Providing IPR policy to academic institutions has a favorable outcome and 
various settlements for shareholders. The most significant overarching advantage 
of these IPR policies was pronounced increases involvement in improving the 
global innovation performance, i.e., ultimately leading to improving the marketable 
products and processes. The development of spin-out companies from universities 
is also growing at a faster rate. The critical part is that the university should own 
the background IP. Then a resource of external financial support is necessary to 
finance the start-up company. IPR affairs at academic institutions glow enormous 
meandering return impending for the national economy. Publishing articles 
regarding innovations play an essential role in the profession of academic scientists. 
Participating in knowledge transfer from academia to manufacturing industries 
can promote academic entrepreneurship. Moreover, these patents have precious 
information than other publishing articles. Thus, utilizing and increasing patent 
writing might be beneficial in scientific research. Appropriate IPR policies and 
tractable technology transfer professionals play a pivotal role in streamlining the 
necessary work-frame. Published patents improve the economy and reputation of 
the academic institutions as well as the researchers.
7. Conclusion
Nanomaterials, due to their nano-size and unique physicochemical proper-
ties, have contributed significantly to the advance of biomedicine. The scope of 
nanomedicine also relies on the intelligent engineering of different nanoparticles 
with tunable attributes to modulate their nano-bio communications for biomedi-
cal applications. Elucidation of nanoparticle interactions with biological systems 
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will help find favorable physicochemical properties to enhance biocompatibility 
and therapeutic efficacy with no adverse effects. A complete toxicological evalu-
ation of engineered nanomaterials is still inadequately understood, restraining 
the successful translation of nanomedicine. Nanoparticle surface functionaliza-
tion with specific targeting moieties can effectively develop ideal nanoparticle 
delivery systems for various biomedical applications and targeted therapeutics. 
Hence, in vitro 2D and 3D cell culture systems can accelerate biocompatibility 
and biotoxicity studies to drive the disease-specific application of nanoparticles 
[60]. Nanoparticles are progressively used in a wide variety of cell and tissue-
specific biological analyses, including cell analysis, in vivo imaging, biosensors, 
and theranostics. Hence the issue of biosafety and bioethics has become a vital 
issue while using mammalian cell cultures. This chapter summarizes the criti-
cal aspects of biosafety and bioethics associated with nanomaterial-associated 
studies.
In conclusion, MCC is an essential tool in modern-day biomedicine, and its 
applications are countless in the diagnosis and therapy of human diseases. Cell 
culture procedures are reliable, reproducible, and unbiased, but culturing the 
cells is complex at times. The vast opportunities to employ MCC procedures 
to address rudimentary and translational research queries have elucidated the 
essential attentions for setting up a cell culture laboratory. Especially 3D organoid 
culture methods have created a cellular environment that mimics the in vivo 
environment.
Genome sequencing, mapping, and annotating its genetic code have become 
a priority in biotechnology, especially intending to understand the interaction of 
nanoparticles and mammalian cells. Reporting and cataloging the identified gene 
sequences can be critical for the progress of science and also for disease-specific 
therapeutics. Nanotechnology-based research has contributed significantly to 
many scientific fields and associated industries. Hence nanotechnology, combined 
with the mammalian cell culture system, can result in a research solution and can 
deliver considerable benefits to society at large. Hence the importance of intel-
lectual property rights for protecting the innovator’s right over the discovery. A 
good understanding of the IPR policies and technology transfer protocol is vital. 
Academic institutions and government organizations can assist in creating a 
congenial platform for efficient policy management. A deeper understanding of 
nanoparticle-cell interaction and the design of futuristic nanocarriers can open up 
an era of next-generation therapeutics and theranostics.
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